

Levagen[®]+



Is a high quality, water dispersible Palmitoylethanolamide (PEA)

Naturally occurring analgesic (painkiller), anti-inflammatory and immune-modulating properties¹

Is clinically tested

Is GRAS affirmed

Is an award-winning ingredient

What Is PEA?

(PEA) is an endogenous fatty acid amide

PEA is naturally produced in the human body

Levels of PEA drop in response to pain, stress and inflammation

PEA reduces local inflammation and pain

Safe and efficacious alternative to CBD

NOT CBD

PEA mediates some of the same key set of receptors as CBD



CB1, CB2, GPR55, PPAR & TRPV1 protein receptor



Helps repair muscle tissue, minimize pain & aids with sports-related inflammation



Levagen is backed by multiple human clinical studies




Scientifically researched to manage mild to moderate osteoarthritis symptoms*



It is a safe & effective alternative to CBD for athletes



Helps athletes with quicker muscle recovery & improved performance*



Legal, no EFSA or FDA Challenges




Helps support sleep*



Quality manufacturing to cGMP standards



Clinically proven to support joint health and comfort*



2018

Safety & efficacy of PEA/Levagen for the management of mild to moderate osteoarthritis symptoms²

2019

Pharmacokinetic Study – measure the bioavailability uptake of Levagen+³

2020

Exercise Recovery Study – measure the effects of Levagen+ on exercise recovery⁴

2020

Ongoing Immunity Study

Clinical Studies



Formats



Superior absorption (x 1.75) powered by LipiSpense[®] Technology

Cold water dispersible

Same efficacy, if not better, at lower dosages

Fast Acting

Soft Gel Capsules; Hard piece capsules, Effervescent tablets & Powders; Ready-Mix powders; Beverages or Liquids; Shots; Gels



Benefits

IMMUNITY*

JOINT HEALTH*

PAIN RELIEF*

SPORTS RECOVERY*

SLEEP*

FAST ACTING

ANTI-INFLAMMATION*

* These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure or prevent any disease. Not all claims made are valid in all global regions.

1. Petrosino S, et al. The anti-inflammatory mediator palmitoylethanolamide enhances the levels of 2-arachidonoyl-glycerol and potentiates its actions at TRPV1 cation channels. *Br J Pharmacol*. 2015.
 2. Steels E, et al. A double-blind randomized placebo-controlled study assessing safety, tolerability and efficacy of palmitoylethanolamide for symptoms of knee osteoarthritis. 2018.
 3. Briskley D, et al. Increased Bioavailability of Palmitoylethanolamide using a Novel Dispersion Technology System (LipiSpense[®]). 2019.
 4. Mallard A, et al. The Effect of Orally Dosed Levagen+[™] (palmitoylethanolamide) on Exercise Recovery in Healthy Males—A Double-Blind, Randomized, Placebo-Controlled Study. 2020.